Jankowski Jess's Form 4/A amendment
AmendedSolesence, Inc. (SLSN) · filed Nov 7, 2022
- Accession no.
- 0001209191-22-055965
- Filed
- Nov 7, 2022, 5:00 PM ET
- Trade date
- Nov 2-4, 2022
- Filing delay
- 5 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
- Original filed
- Nov 4, 2022
This filing lists 6 non-derivative transactions and 3 derivative transactions. Open-market sales total $30.0K. It was filed 5 days after the trade.
This amendment replaces 0001209191-22-055875 (filed Nov 4, 2022).
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Jankowski JessCIK 0001184478 | Director, Officer (President, CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 2, 2022 | Common Stock | MOption exerciseAcquired | +7,400 | $0.415F1 | +$3,071 | 66,400 | Direct | |
| Nov 2, 2022 | Common Stock | SSaleDisposed | −7,400 | $2.42 | −$17,908 | 59,000 | Direct | |
| Nov 3, 2022 | Common Stock | MOption exerciseAcquired | +4,283 | $0.415 | +$1,777.45 | 63,283 | Direct | |
| Nov 3, 2022 | Common Stock | SSaleDisposed | −4,283 | $2.30 | −$9,850.9 | 59,000 | Direct | |
| Nov 4, 2022 | Common Stock | MOption exerciseAcquired | +1,000 | $0.415 | +$415 | 60,000 | Direct | |
| Nov 4, 2022 | Common Stock | SSaleDisposed | −1,000 | $2.28 | −$2,280 | 59,000 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 2, 2022 | Common Stock | MOption exerciseDisposed | −86,700 | $0.415 | −$3,071 | 79,300 | Direct | |
| Nov 3, 2022 | Common Stock | MOption exerciseDisposed | −79,300 | $0.415 | −$1,777.45 | 75,017 | Direct | |
| Nov 4, 2022 | Common Stock | MOption exerciseDisposed | −75,017 | $0.415 | −$415 | 74,017 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
These stock options are set to expire on 02/14/2023. Mr. Jankowski established a 10b5-1 Plan with an independent broker with a goal of having his broker sell shares from this grant, under fixed guidleines, in a regular and measured manner designed to avoid both forfeiture of shares due to expiration, and impacting the stock price due to excessive trading volume. His Plan was approved in advance by the Compensation & Governance Committee of the Nanophase Board of Directors.
Referenced by the price of 1 transaction in Table I.
- F2
These stock options are set to expire on 02/14/2023. Mr. Jankowski converted and sold these shares through a 10b5-1 Plan that has been established with an independent broker. His goal is to have this broker sell shares from this grant, under fixed guidleines, in a regular and measured manner designed to avoid both forfeiture of shares due to expiration, and impacting the stock price due to excessive trading volume. His Plan was approved in advance by the Compensation & Governance Committee of the Nanophase Board of Directors.
- F3
Subject to certain restrictions, beginning on this date, options vest in three equal installments.
- F4
Subject to certain restrictions, beginning on this date, the options vest in three equal annual installments.
- F5
Subject to certain restrictions, beginning on this date, options vest in three equal annual installments.
Remarks
This filing was amended to reflect the correction of an input error on the conversion of a stock option to common stock on November 4, 2022. The original filing listed the acquisition price of the shares at the sale price, instead of the strike price of the common stock option being exercised. The entry on the seventh line in Table I under "Price" was changed from $2.28 to $0.415 per share. Mr. Jankowski established a 10b5-1 Plan with an independent broker with a goal of having shares from this grant sold, under fixed guidleines, in a regular and measured manner designed to avoid both forfeiture of shares due to expiration, and impacting the stock price due to excessive trading volume. His Plan was approved in advance by the Compensation & Governance Committee of the Nanophase Board of Directors. The maturity of these rights cannot be extended beyond the IRS statutory limit of ten years.